John H. Growdon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
John H. Growdon has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Alberto Serrano-Pozo
Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
1 shared publicationAndrea Santarlasci
From the Departments of Neurology (S.N.G., J.J.L., D.R., A.S., M.M., K.A.J., J.H.G.) and Radiology (K.A.J.), Massachusetts General Hospital, Boston; and Autonomous University of Barcelona–Medicine Doctoral Studies (M.M.), Barcelona, Spain
1 shared publicationBradley T. Hyman
1 shared publication- Bradley T. Hyman
Massachusetts General Hospital, Department of Neurology, Boston, MA, USA
1 shared publication Dorene Rentz
From the Departments of Neurology (S.N.G., J.J.L., D.R., A.S., M.M., K.A.J., J.H.G.) and Radiology (K.A.J.), Massachusetts General Hospital, Boston; and Autonomous University of Barcelona–Medicine Doctoral Studies (M.M.), Barcelona, Spain
1 shared publicationErica R. Lee-Cherry
1 shared publication
Latest Publications
- 12 February 2019
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 67 (3) , 795-819
Is Alzheimer’s Disease Risk Modifiable?
Population-based clinic-pathological studies have established that the most common pathological substrate of dementia in community-dwelling elderly people is mixed, especially Alzheimer’s disease (AD) and cerebrovascular ischemic disease (CVID), rath
- 12 February 2019
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 67 (3) , 795-819
Is Alzheimer’s Disease Risk Modifiable?
Population-based clinic-pathological studies have established that the most common pathological substrate of dementia in community-dwelling elderly people is mixed, especially Alzheimer’s disease (AD) and cerebrovascular ischemic disease (CVID), rath
- 1 January 2013
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (1) , 85-91
Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia
Objective: To determine whether amyloid burden, as indexed by Pittsburgh compound B (PiB) retention, identifies patients with Parkinson disease with mild cognitive impairment (PD-MCI) compared to those with normal cognition (PD-nl). A related aim is to determine whether amyloid burden predicts cognitive decline in a cohort of subjects with PD without dementia. Methods: In this prospective cohort study, we examined 46 subjects with PD without dementia, of whom 35 had normal cognition and 11 met criteria for PD-MCI at study baseline. All subjects underwent standardized neurologic and neuropsychological examinations and PiB PET at baseline, and clinical examinations were conducted annually for up to 5 years. Results: At baseline, precuneus PiB retention did not distinguish PD-MCI from PD-nl. Subjects with PD-MCI declined more rapidly than PD-nl subjects on cognitive tests of memory, executive function, and activation retrieval. Of the 35 PD-nl subjects, 8 progressed to PD-MCI and 1 to dementia; of the 11 PD-MCI subjects, 5 converted to dementia. Both higher PiB retention and a diagnosis of PD-MCI predicted a greater hazard of conversion to a more severe diagnosis. Baseline PiB retention predicted worsening in executive function over time. The APOE ε4 allele also related to worsening in executive function, as well as visuospatial function, activation retrieval, and performance on the Mini-Mental State Examination. In contrast to its relation to cognitive decline, PiB retention did not affect progression of motor impairment. Conclusions: At baseline measurements, amyloid burden does not distinguish between cognitively impaired and unimpaired subjects with PD without dementia, but our data suggest that amyloid contributes to cognitive, but not motor, decline over time.
- 1 January 2013
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (1) , 85-91
Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia
Objective: To determine whether amyloid burden, as indexed by Pittsburgh compound B (PiB) retention, identifies patients with Parkinson disease with mild cognitive impairment (PD-MCI) compared to those with normal cognition (PD-nl). A related aim is to determine whether amyloid burden predicts cognitive decline in a cohort of subjects with PD without dementia. Methods: In this prospective cohort study, we examined 46 subjects with PD without dementia, of whom 35 had normal cognition and 11 met criteria for PD-MCI at study baseline. All subjects underwent standardized neurologic and neuropsychological examinations and PiB PET at baseline, and clinical examinations were conducted annually for up to 5 years. Results: At baseline, precuneus PiB retention did not distinguish PD-MCI from PD-nl. Subjects with PD-MCI declined more rapidly than PD-nl subjects on cognitive tests of memory, executive function, and activation retrieval. Of the 35 PD-nl subjects, 8 progressed to PD-MCI and 1 to dementia; of the 11 PD-MCI subjects, 5 converted to dementia. Both higher PiB retention and a diagnosis of PD-MCI predicted a greater hazard of conversion to a more severe diagnosis. Baseline PiB retention predicted worsening in executive function over time. The APOE ε4 allele also related to worsening in executive function, as well as visuospatial function, activation retrieval, and performance on the Mini-Mental State Examination. In contrast to its relation to cognitive decline, PiB retention did not affect progression of motor impairment. Conclusions: At baseline measurements, amyloid burden does not distinguish between cognitively impaired and unimpaired subjects with PD without dementia, but our data suggest that amyloid contributes to cognitive, but not motor, decline over time.
- 1 June 2011
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 68 (6) , 799-801
Plasma β-Amyloid Linked to Cognitive Decline
JAMA Association of Plasma β-Amyloid Level and Cognitive Reserve With Subsequent Cognitive Decline Kristine Yaffe, MD; Andrea Weston, MPH; Neill R. Graff-Radford, MBBCh; Suzanne Satterfield, MD, DrPh; Eleanor M. Simonsick, PhD; Steven G. Younkin, MD, PhD; Linda H. Younkin, PhD; Lewis Kuller, MD, DrPh; Hilsa N. Ayonayon, PhD; Jingzhong Ding, MD, PhD; Tamara B. Harris, MD, MS Context: Lower plasma β-amyloid 42 and 42/40 levels have been associated with incident dementia, but results are conflicting and few have investigated cognitive decline among elders without dementia. Objective: To determine if plasma β-amyloid is associated with cognitive decline and if this association is modified by measures of cognitive reserve. Design, Setting, and Participants: We studied 997 black and white community-dwelling older adults from Memphis, Tennessee, and Pittsburgh, Pennsylvania, who were enrolled in the Health ABC Study, a prospective observational study begun in 1997-1998 with 10-year follow-up in 2006-2007. Participant mean age was 74.0 (SD, 3.0) years; 55.2% (n = 550) were female; and 54.0% (n = 538) were black. Main Outcome Measures: Association of near-baseline plasma β-amyloid levels (42 and 42/40 measured in 2010) and repeatedly measured Modified Mini-Mental State Examination (3MS) results. Results: Low β-amyloid 42/40 level was associated with greater 9-year 3MS cognitive decline (lowest β-amyloid tertile: mean change in 3MS score, −6.59 [95% confidence interval [CI], −5.21 to −7.67] points; middle tertile: −6.16 [95% CI, −4.92 to −7.32] points; and highest tertile: −3.60 [95% CI, −2.27 to −4.73] points; P < .001). Results were similar after multivariate adjustment for age, race, education, diabetes, smoking, and apolipoprotein E [APOE ] e4 status and after excluding the 72 participants with incident dementia. Measures of cognitive reserve modified this association whereby among those with high reserve (at least a high school diploma, higher than sixth-grade literacy, or no APOE e4 allele), β-amyloid 42/40 was less associated with multivariate adjusted 9-year decline. For example, among participants with less than a high school diploma, the 3MS score decline was −8.94 (95% CI, −6.94 to −10.94) for the lowest tertile compared with −4.45 (95% CI, −2.31 to −6.59) for the highest tertile, but for those with at least a high school diploma, 3MS score decline was −4.60 (95% CI, −3.07 to −6.13) for the lowest tertile and −2.88 (95% CI, −1.41 to −4.35) for the highest tertile (P = .004 for interaction). Interactions were also observed for literacy (P = .005) and for APOE e4 allele (P = .02). Conclusion: Lower plasma β-amyloid 42/40 is associated with greater cognitive decline among elderly persons without dementia over 9 years, and this association is stronger among those with low measures of cognitive reserve. JAMA. 2011;305(3):261-266.
- 1 June 2011
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 68 (6) , 799-801
Plasma β-Amyloid Linked to Cognitive Decline
JAMA Association of Plasma β-Amyloid Level and Cognitive Reserve With Subsequent Cognitive Decline Kristine Yaffe, MD; Andrea Weston, MPH; Neill R. Graff-Radford, MBBCh; Suzanne Satterfield, MD, DrPh; Eleanor M. Simonsick, PhD; Steven G. Younkin, MD, PhD; Linda H. Younkin, PhD; Lewis Kuller, MD, DrPh; Hilsa N. Ayonayon, PhD; Jingzhong Ding, MD, PhD; Tamara B. Harris, MD, MS Context: Lower plasma β-amyloid 42 and 42/40 levels have been associated with incident dementia, but results are conflicting and few have investigated cognitive decline among elders without dementia. Objective: To determine if plasma β-amyloid is associated with cognitive decline and if this association is modified by measures of cognitive reserve. Design, Setting, and Participants: We studied 997 black and white community-dwelling older adults from Memphis, Tennessee, and Pittsburgh, Pennsylvania, who were enrolled in the Health ABC Study, a prospective observational study begun in 1997-1998 with 10-year follow-up in 2006-2007. Participant mean age was 74.0 (SD, 3.0) years; 55.2% (n = 550) were female; and 54.0% (n = 538) were black. Main Outcome Measures: Association of near-baseline plasma β-amyloid levels (42 and 42/40 measured in 2010) and repeatedly measured Modified Mini-Mental State Examination (3MS) results. Results: Low β-amyloid 42/40 level was associated with greater 9-year 3MS cognitive decline (lowest β-amyloid tertile: mean change in 3MS score, −6.59 [95% confidence interval [CI], −5.21 to −7.67] points; middle tertile: −6.16 [95% CI, −4.92 to −7.32] points; and highest tertile: −3.60 [95% CI, −2.27 to −4.73] points; P < .001). Results were similar after multivariate adjustment for age, race, education, diabetes, smoking, and apolipoprotein E [APOE ] e4 status and after excluding the 72 participants with incident dementia. Measures of cognitive reserve modified this association whereby among those with high reserve (at least a high school diploma, higher than sixth-grade literacy, or no APOE e4 allele), β-amyloid 42/40 was less associated with multivariate adjusted 9-year decline. For example, among participants with less than a high school diploma, the 3MS score decline was −8.94 (95% CI, −6.94 to −10.94) for the lowest tertile compared with −4.45 (95% CI, −2.31 to −6.59) for the highest tertile, but for those with at least a high school diploma, 3MS score decline was −4.60 (95% CI, −3.07 to −6.13) for the lowest tertile and −2.88 (95% CI, −1.41 to −4.35) for the highest tertile (P = .004 for interaction). Interactions were also observed for literacy (P = .005) and for APOE e4 allele (P = .02). Conclusion: Lower plasma β-amyloid 42/40 is associated with greater cognitive decline among elderly persons without dementia over 9 years, and this association is stronger among those with low measures of cognitive reserve. JAMA. 2011;305(3):261-266.
- 1 August 2007
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 2007 (1094687X) , 6290-6293
Analysis of Feature Space for Monitoring Persons with Parkinson's Disease With Application to a Wireless Wearable Sensor System
We present work to develop a wireless wearable sensor system for monitoring patients with Parkinson's disease (PD) in their homes. For monitoring outside the laboratory, a wearable system must not only record data, but also efficiently process data on-board. This manuscript details the analysis of data collected using tethered wearable sensors. Optimal window length for feature extraction and feature ranking were calculated, based on their ability to capture motor fluctuations in persons with PD. Results from this study will be employed to develop a software platform for the wireless system, to efficiently process on-board data.
- 1 August 2007
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 2007 (1094687X) , 6290-6293
Analysis of Feature Space for Monitoring Persons with Parkinson's Disease With Application to a Wireless Wearable Sensor System
We present work to develop a wireless wearable sensor system for monitoring patients with Parkinson's disease (PD) in their homes. For monitoring outside the laboratory, a wearable system must not only record data, but also efficiently process data on-board. This manuscript details the analysis of data collected using tethered wearable sensors. Optimal window length for feature extraction and feature ranking were calculated, based on their ability to capture motor fluctuations in persons with PD. Results from this study will be employed to develop a software platform for the wireless system, to efficiently process on-board data.
- 1 August 1999
- Published by American Psychiatric Association Publishing in The Journal of Neuropsychiatry and Clinical Neurosciences
- Vol. 11 (3) , 336-342
Risperidone Treatment of Behavioral Disturbances in Outpatients With Dementia
The authors retrospectively assessed the effectiveness and side effects of risperidone used to treat behavioral disturbances in elderly outpatients with dementia. In 41 patients treated with risperidone 1.8 +/- 1.4 mg/day, there was complete suppression of the target symptom in 15%, partial response in 41%, and no response in 44%. Risperidone appeared equally effective in treating agitation and psychosis. New or worsening extrapyramidal side effects (EPS) occurred in 32%, associated with longer duration of treatment and possibly with concomitant use of serotonergic anti-depressants. Risperidone was a useful adjunct in the treatment of agitation and psychosis in outpatients with dementia but was limited by EPS in about one-third of patients.
- 1 August 1999
- Published by American Psychiatric Association Publishing in The Journal of Neuropsychiatry and Clinical Neurosciences
- Vol. 11 (3) , 336-342
Risperidone Treatment of Behavioral Disturbances in Outpatients With Dementia
The authors retrospectively assessed the effectiveness and side effects of risperidone used to treat behavioral disturbances in elderly outpatients with dementia. In 41 patients treated with risperidone 1.8 +/- 1.4 mg/day, there was complete suppression of the target symptom in 15%, partial response in 41%, and no response in 44%. Risperidone appeared equally effective in treating agitation and psychosis. New or worsening extrapyramidal side effects (EPS) occurred in 32%, associated with longer duration of treatment and possibly with concomitant use of serotonergic anti-depressants. Risperidone was a useful adjunct in the treatment of agitation and psychosis in outpatients with dementia but was limited by EPS in about one-third of patients.